• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OMEPRAZOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • OMEPRAZOLE chembl:CHEMBL1503 Approved

    Alternate Names:

    ANTRA
    LOSEC MUPS
    MOPRAL
    OMERAN
    PRILOSEC
    MEZZOPRAM
    H-168/68
    H 168/68
    ZANPROL
    LOSEC
    OMEPRAZOLE
    OMEP
    OMEPRAZOL
    PRILOSEC®
    OMEPRAZOLUM
    LOSEC®
    drugbank:00338
    chembl:CHEMBL1503
    pubchem.compound:4594
    chemidplus:73590-58-6
    rxcui:7646

    Drug Info:

    Year of Approval 1989
    Drug Class gi anti-ulcer agents, proton-pump inhibitors
    FDA Approval approved
    Drug Class small molecule
    Drug Indications antiulcer agent
    Drug Indications Proton pump inhibitor
    (6 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Koyano S et al., 2005, Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population., Drug Metab Dispos
    Dzeletovic N et al., 1997, Regulation of dioxin receptor function by omeprazole., J Biol Chem
    Ozdemir et al., 2006, In vitro effects of some drugs on human red blood cell glucose-6-phosphate dehydrogenase enzyme activity., J Enzyme Inhib Med Chem
    Fujisaki et al., 1998, Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats., Jpn. J. Pharmacol.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Shi et al., 2008, Proton pump inhibitors: an update of their clinical use and pharmacokinetics., Eur. J. Clin. Pharmacol.
    Tajima et al., 2008, Proton pump inhibitors and recurrent bleeding in peptic ulcer disease., J. Gastroenterol. Hepatol.
    Kirchheiner et al., 2009, Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH., Eur. J. Clin. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Zuger B, 1978, Effeminate behavior present in boys from childhood: ten additional years of follow-up., Compr Psychiatry
    Shin JM et al., 2009, The gastric HK-ATPase: structure, function, and inhibition., Pflugers Arch
    Munson K et al., 2007, Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites., Biochemistry
    Sachs G et al., 2006, Review article: the clinical pharmacology of proton pump inhibitors., Aliment Pharmacol Ther
    Kashfi et al., 1995, Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human., Clin. Pharmacol. Ther.
    Katagiri et al., 2005, Omeprazole raises somatostatin and motilin in human plasma., Biol. Pharm. Bull.
    Yoshinari K et al., 2008, Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements., Biochem Pharmacol
    Kountouras et al., Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease., Hepatogastroenterology
    Swarovsky et al., 1994, Expression of the gastric H+/K(+)-ATPase and histidine decarboxylase during omeprazole treatment., Digestion
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Backlund et al., 1997, Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells., J. Biol. Chem.
    Zhao W et al., 2018, Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug., Br J Clin Pharmacol
    Gawrońska-Szklarz B et al., 2005, Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection., Eur J Clin Pharmacol
    Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
    Mózsik et al., 2005, Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds., Inflammopharmacology
    Handa et al., 2006, Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors., Inflamm. Res.
    Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther
    Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol
  • OMEPRAZOLE   HDC

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8187977


    Sources:
    NCI

  • OMEPRAZOLE   ATP4A

    Interaction Score: 1.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CGT-2168
    Novel drug target Established target
    Mechanism of Interaction Potassium-transporting ATPase inhibitor

    PMIDs:
    18679668 19120905 18925391 11752352 679668 18536934 17425287 16700898


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • OMEPRAZOLE   VIP

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15684503


    Sources:
    NCI

  • OMEPRAZOLE   HEXB

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9593221


    Sources:
    NCI

  • OMEPRAZOLE   TAC1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16259735 15684503


    Sources:
    NCI

  • OMEPRAZOLE   IL1B

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21054464 16815316 14638340


    Sources:
    PharmGKB

  • OMEPRAZOLE   ATP4B

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Potassium-transporting ATPase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OMEPRAZOLE   AHR

    Interaction Score: 0.1

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    15860653 9139728


    Sources:
    PharmGKB

  • OMEPRAZOLE   CSF2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11100337


    Sources:
    NCI

  • OMEPRAZOLE   GSTP1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8529327


    Sources:
    NCI

  • OMEPRAZOLE   CXCL8

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17122965


    Sources:
    NCI

  • OMEPRAZOLE   HSPB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   TNF

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16815316


    Sources:
    NCI

  • OMEPRAZOLE   G6PD

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16570509


    Sources:
    NCI

  • OMEPRAZOLE   MCL1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • OMEPRAZOLE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29377228 15976989


    Sources:
    PharmGKB

  • OMEPRAZOLE   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OMEPRAZOLE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 18502397


    Sources:
    DTC PharmGKB

  • OMEPRAZOLE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528 9395520 22931300


    Sources:
    DTC NCI PharmGKB

  • OMEPRAZOLE   PLK1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • OMEPRAZOLE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC FDA

  • OMEPRAZOLE   HPGD

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   KDM4E

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • OMEPRAZOLE   BAZ2B

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   MAPT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   KDM4A

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OMEPRAZOLE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: OMEPRAZOLE

    • Version: 01-August-2011

    Alternate Names:
    OMEPRAZOLE Primary Drug Name

    Drug Info:
    Drug Class gi anti-ulcer agents, proton-pump inhibitors
    Year of Approval 1989

    Publications:

  • TdgClinicalTrial: OMEPRAZOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiulcer agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • TdgClinicalTrial: OMEPRAZOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiulcer agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: OMEPRAZOLE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1503 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • NCI: OMEPRAZOLE

    • Version: 14-September-2017

    Alternate Names:
    C716 NCI drug code

    Drug Info:

    Publications:
    Katagiri et al., 2005, Omeprazole raises somatostatin and motilin in human plasma., Biol. Pharm. Bull.
    Mózsik et al., 2005, Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds., Inflammopharmacology
    Handa et al., 2006, Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors., Inflamm. Res.

  • PharmGKB: omeprazole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
    Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther
    Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol

  • TTD: Omeprazole

    • Version: 2020.06.01

    Alternate Names:
    D01XNB TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1503

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Omeprazole

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1503

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21